Derms on Drugs

Listening this week could save your life (well, at least your kidneys).  Find out what common ingredient in keratin treatments you (and your friends, family and patients) NEED to avoid.  But there's a lot more than that packed into this week's episode.  As always, the Derms on Drugs bring the goods on the latest questions that the literature is answering:-Is isotretinoin making kids short?  -Is Dupixent making them tall?  -What is "transcutaneous auricular vagus nerve stimulation" and which common but difficult derm disease does it help with?  -What OTC supplement makes NBUVB work better for vitiligo?  -What oral drug can you add to isotretinoin to make it work even better?  -Does oral tranexamic acid increase the risk of blood clots when used in dermatology?-How well does Opzelura work for hidradenitis suppurativa?-Do Humira biosimilars work as well as Humira in hidradenitis suppurativa?-What common statistical technique used by pharma is total BS?-Which ingredient in 'keratin treatments" is causing kidney failure and kidney stones? 

Admit it—bad hair days are the worst. Now imagine every day is one. Alopecia’s psychological impact is way deeper (and more surprising) than most people think. This week, the Derms on Drugs sit down with Harvard’s Dr. Maryanne Makredes Senna to unpack the mental side of AA—and then dive into what to do when a JAK inhibitor just… doesn’t JAK. As always, we’re answering the questions you didn’t even know you had.Here’s what we’re tackling:What hits harder on anxiety and depression—scarring or non-scarring alopecia?How tightly does AA severity track with psychological burden?How should you approach the mental health effects of AA?(Yes, you should ask. No, you shouldn’t be the one treating—here’s how to bridge patients to the right therapists.)And what do you do when a JAK Inhibitor isn’t giving you the results you hoped for?

This week, the Derms on Drugs are back with another literature speed-run—think 3D chess meets derm nerd nirvana. We’re answering questions you didn’t even know you had (and a few you wish you didn’t).Here’s what we’re tackling:Do herbal supplements turn up dermatomyositis?Can biologics cut down on blood clots in HS?Wait… does Claritin supercharge isotretinoin?Is Sotyktu stirring up rosacea?How good is the new oral IL-23 inhibitor icotrokinra for psoriasis?Any fresh weapons against demodex?Anything new for those stubborn pemphigus oral lesions?What to do when your patient is resistant to multiple botulinum toxins?And—holy grail alert—can we actually prevent chemo-induced alopecia in breast cancer?

The Derms on Drugs are joined by Dr. Crystal Aguh from Johns Hopkins for an AMAZING discussion on central centrifugal scarring alopecia.  From uber practical, cheap, safe, effective treatment approaches to deep science on what is happening in this disease, listen this week and you'll be an expert - how to talk to these patients, the baseline treatments everybody should be on, when to get more aggressive, when to step therapy back - the whole enchilada.  We even throw in a little frontal fibrosing alopecia.  Quite honestly one of the best episodes we've ever done.  The Derms on Drugs learned new approaches to this disease and we promise, you will too!

Join us this week as the Derms on Drugs crew discusses the latest in the Dermatology literature.  Topics for this episode include: - Cutaneous vasculitis of the skin (it’s a Chapel Hill thing)- Ozempic face, butt, and body- TAC injections for AA – what concentration do you use?- Does the MERLIN study deserve its magical name?- Are systemic JAK inhibitors the answer for vitiligo?- And everyone’s favorite – Demodex mites!